Key Findings from COMFORT I and II Trials

Opinion
Video

Dr. Bose discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages patients with myelofibrosis, along with the factors that most inform his treatment decisions.

Case: Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman

Clinical Presentation:

  • A 68-year-old woman presented to her physician with symptoms of mild fatigue.
  • Spleen was palpable 6-7 cm below the left costal margin.

PM: No known comorbidities

Initial Clinical Workup and Diagnosis:

  • NGS Testing: JAK2 V617F mutation
  • Karyotype: 46XX
  • BM biopsy: megakaryocyte proliferation and atypia with evidence of reticulin fibrosis
  • Blood smear: leukoerythroblastosis
  • Diagnosis: Primary myelofibrosis
  • Risk:
    • DIPSS: Intermediate-2
    • Mipss70: Intermediate risk
  • Lab Values
    • RBC 3.40 x 1012/L
    • Hgb 9.7 g/dL
    • HCT 32.3%
    • MCV 94 fL
    • WBC 23.0 x 109/L
    • PLT 450 x 109/L
    • PB Blasts <1%

Initial Treatments:

  • Initiated on ruxolitinib.
    • The patient was not interested in transplant.
Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Hannah Choe, MD, an expert on GVHD
Corey Cutler, MD, MPH, an expert on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
1 KOL is featured in this series.
Guillermo Garcia-Manero, MD, an expert on MDS
Related Content
FDA Accepts Remestemcel-L BLA Resubmission for Acute GVHD

FDA Accepts Remestemcel-L BLA Resubmission for Acute GVHD

Sabrina Serani
July 23rd 2024
Article

The FDA has accepted the resubmitted application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants.

Read More

FDA Grants Rare Pediatric Disease Designation to SLS009 in Pediatric AML

FDA Grants Rare Pediatric Disease Designation to SLS009 in Pediatric AML

Jordyn Sava
July 16th 2024
Article

The FDA has granted a rare pediatric disease designation to SLS009 for treating pediatric acute myeloid leukemia.

Read More

FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML

FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML

Jordyn Sava
July 16th 2024
Article

Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Read More

FDA Fast Tracks DSP-5336 in NPM1/KMT2A+ Acute Leukemia

FDA Fast Tracks DSP-5336 in NPM1/KMT2A+ Acute Leukemia

Jordyn Sava
July 15th 2024
Article

The FDA granted a fast track designation to DSP-5336 in relapsed/refractory AML with a KMT2A rearrangement or NPM1 mutation, showing promising results and safety in early trials.

Read More

FDA Wraps Up End Of Phase 2 Meeting for AML Combination Therapy

FDA Wraps Up End Of Phase 2 Meeting for AML Combination Therapy

Jordyn Sava
July 10th 2024
Article

The completion of the End of Phase 2 meeting for the phase 1B/2 trial of annamycin and cytarabine in acute myeloid leukemia has been announced.

Read More

COMMANDS Trial Shows Positive Result in MDS Despite Pandemic

COMMANDS Trial Shows Positive Result in MDS Despite Pandemic

Targeted Oncology Staff
July 9th 2024
Article

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.

Read More